670 related articles for article (PubMed ID: 17290305)
1. Nonsense-mediated mRNA decay affects nonsense transcript levels and governs response of cystic fibrosis patients to gentamicin.
Linde L; Boelz S; Nissim-Rafinia M; Oren YS; Wilschanski M; Yaacov Y; Virgilis D; Neu-Yilik G; Kulozik AE; Kerem E; Kerem B
J Clin Invest; 2007 Mar; 117(3):683-92. PubMed ID: 17290305
[TBL] [Abstract][Full Text] [Related]
2. The efficiency of nonsense-mediated mRNA decay is an inherent character and varies among different cells.
Linde L; Boelz S; Neu-Yilik G; Kulozik AE; Kerem B
Eur J Hum Genet; 2007 Nov; 15(11):1156-62. PubMed ID: 17625509
[TBL] [Abstract][Full Text] [Related]
3. Gentamicin-induced correction of CFTR function in patients with cystic fibrosis and CFTR stop mutations.
Wilschanski M; Yahav Y; Yaacov Y; Blau H; Bentur L; Rivlin J; Aviram M; Bdolah-Abram T; Bebok Z; Shushi L; Kerem B; Kerem E
N Engl J Med; 2003 Oct; 349(15):1433-41. PubMed ID: 14534336
[TBL] [Abstract][Full Text] [Related]
4. Pharmacological induction of CFTR function in patients with cystic fibrosis: mutation-specific therapy.
Kerem E
Pediatr Pulmonol; 2005 Sep; 40(3):183-96. PubMed ID: 15880796
[TBL] [Abstract][Full Text] [Related]
5. Nonsense-mediated mRNA decay and cystic fibrosis.
Linde L; Kerem B
Methods Mol Biol; 2011; 741():137-54. PubMed ID: 21594783
[TBL] [Abstract][Full Text] [Related]
6. In vitro prediction of stop-codon suppression by intravenous gentamicin in patients with cystic fibrosis: a pilot study.
Sermet-Gaudelus I; Renouil M; Fajac A; Bidou L; Parbaille B; Pierrot S; Davy N; Bismuth E; Reinert P; Lenoir G; Lesure JF; Rousset JP; Edelman A
BMC Med; 2007 Mar; 5():5. PubMed ID: 17394637
[TBL] [Abstract][Full Text] [Related]
7. Tobramycin is a suppressor of premature termination codons.
Altamura N; Castaldo R; Finotti A; Breveglieri G; Salvatori F; Zuccato C; Gambari R; Panin GC; Borgatti M
J Cyst Fibros; 2013 Dec; 12(6):806-11. PubMed ID: 23540394
[TBL] [Abstract][Full Text] [Related]
8. Synergy between Readthrough and Nonsense Mediated Decay Inhibition in a Murine Model of Cystic Fibrosis Nonsense Mutations.
McHugh DR; Cotton CU; Hodges CA
Int J Mol Sci; 2020 Dec; 22(1):. PubMed ID: 33396210
[TBL] [Abstract][Full Text] [Related]
9. Mutation specific therapy in CF.
Kerem E
Paediatr Respir Rev; 2006; 7 Suppl 1():S166-9. PubMed ID: 16798551
[TBL] [Abstract][Full Text] [Related]
10. Introducing sense into nonsense in treatments of human genetic diseases.
Linde L; Kerem B
Trends Genet; 2008 Nov; 24(11):552-63. PubMed ID: 18937996
[TBL] [Abstract][Full Text] [Related]
11. Gene-specific nonsense-mediated mRNA decay targeting for cystic fibrosis therapy.
Kim YJ; Nomakuchi T; Papaleonidopoulou F; Yang L; Zhang Q; Krainer AR
Nat Commun; 2022 May; 13(1):2978. PubMed ID: 35624092
[TBL] [Abstract][Full Text] [Related]
12. Nonsense-mediated RNA Decay Pathway Inhibition Restores Expression and Function of W1282X CFTR.
Keenan MM; Huang L; Jordan NJ; Wong E; Cheng Y; Valley HC; Mahiou J; Liang F; Bihler H; Mense M; Guo S; Monia BP
Am J Respir Cell Mol Biol; 2019 Sep; 61(3):290-300. PubMed ID: 30836009
[TBL] [Abstract][Full Text] [Related]
13. Synthetic aminoglycosides efficiently suppress cystic fibrosis transmembrane conductance regulator nonsense mutations and are enhanced by ivacaftor.
Xue X; Mutyam V; Tang L; Biswas S; Du M; Jackson LA; Dai Y; Belakhov V; Shalev M; Chen F; Schacht J; J Bridges R; Baasov T; Hong J; Bedwell DM; Rowe SM
Am J Respir Cell Mol Biol; 2014 Apr; 50(4):805-16. PubMed ID: 24251786
[TBL] [Abstract][Full Text] [Related]
14. Incomplete nonsense-mediated mRNA decay in Giardia lamblia.
Chen YH; Su LH; Sun CH
Int J Parasitol; 2008 Sep; 38(11):1305-17. PubMed ID: 18430426
[TBL] [Abstract][Full Text] [Related]
15. Pharmacologic therapy for stop mutations: how much CFTR activity is enough?
Kerem E
Curr Opin Pulm Med; 2004 Nov; 10(6):547-52. PubMed ID: 15510065
[TBL] [Abstract][Full Text] [Related]
16. Ataluren (PTC124) induces cystic fibrosis transmembrane conductance regulator protein expression and activity in children with nonsense mutation cystic fibrosis.
Sermet-Gaudelus I; Boeck KD; Casimir GJ; Vermeulen F; Leal T; Mogenet A; Roussel D; Fritsch J; Hanssens L; Hirawat S; Miller NL; Constantine S; Reha A; Ajayi T; Elfring GL; Miller LL
Am J Respir Crit Care Med; 2010 Nov; 182(10):1262-72. PubMed ID: 20622033
[TBL] [Abstract][Full Text] [Related]
17. Therapeutic benefit observed with the CFTR potentiator, ivacaftor, in a CF patient homozygous for the W1282X CFTR nonsense mutation.
Mutyam V; Libby EF; Peng N; Hadjiliadis D; Bonk M; Solomon GM; Rowe SM
J Cyst Fibros; 2017 Jan; 16(1):24-29. PubMed ID: 27707539
[TBL] [Abstract][Full Text] [Related]
18. Nonsense-mediated mRNA decay (NMD) silences the accumulation of aberrant trypsin proteinase inhibitor mRNA in Nicotiana attenuata.
Wu J; Kang JH; Hettenhausen C; Baldwin IT
Plant J; 2007 Aug; 51(4):693-706. PubMed ID: 17587303
[TBL] [Abstract][Full Text] [Related]
19. Similar levels of mRNA from the W1282X and the delta F508 cystic fibrosis alleles, in nasal epithelial cells.
Shoshani T; Kerem E; Szeinberg A; Augarten A; Yahav Y; Cohen D; Rivlin J; Tal A; Kerem B
J Clin Invest; 1994 Apr; 93(4):1502-7. PubMed ID: 7512981
[TBL] [Abstract][Full Text] [Related]
20. CFTR mRNAs with nonsense codons are degraded by the SMG6-mediated endonucleolytic decay pathway.
Sanderlin EJ; Keenan MM; Mense M; Revenko AS; Monia BP; Guo S; Huang L
Nat Commun; 2022 Apr; 13(1):2344. PubMed ID: 35487895
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
